Pericapsular Nerve Block Versus Interscalene Nerve Block for Acute Pain Management in Shoulder Arthroscopy

NCT ID: NCT05788367

Last Updated: 2023-10-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-15

Study Completion Date

2024-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to compare PENG and ISB after shoulder arthroscopy for postoperative pain management after shoulder arthroscopy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Shoulder arthroscopy is a common procedure done is orthopedics for many surgical indications as rotator cuff tears, stiffness and instability. This procedure has a well - documented postoperative pain. To improve the outcome after surgery, effective pain control is needed.

Various methods are used for postoperative pain management. Intravenous opioid agents are among them, but they may cause undesirable side effects, such as respiratory depression, sedation, constipation, allergic reaction, nausea, and vomiting. Thus, alternative techniques are preferred.

Interscalene brachial plexus blocks (ISBPBs) are often used to provide perioperative analgesia and anesthesia for shoulder surgery. They target nerve roots C4-C6 and thereby provide regional analgesia to the shoulder and upper arm. Although ISBPBs are often performed in combination with general anesthesia (GA) to enhance postoperative analgesia, they are also sometimes used as a sole means of anesthesia.

The pericapsular nerve group (PENG) block is an ultrasound-guided approach, first described by Giron-Arango et al. for the blockade of the articular branches of the femoral, obturator and accessory obturator nerves that provide sensory innervation to the anterior hip capsule. It has been successfully used as an alternative regional anaesthesia technique for the management of acute pain after hip fracture, and for analgesia after elective hip surgery

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pericapsular Nerve Block Interscalene Nerve Block Shoulder Arthroscopy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

The pericapsular nerve group

patients received Ultrasound guided The pericapsular nerve group block using 20 ml of bupivacaine 0.5%

Group Type ACTIVE_COMPARATOR

The pericapsular nerve group

Intervention Type PROCEDURE

patients received Ultrasound guided pericapsular nerve group block using 20 ml of bupivacaine 0.5%

Interscalene group

patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5% before induction of general anesthesia.

Group Type ACTIVE_COMPARATOR

Interscalene brachial plexus block

Intervention Type PROCEDURE

patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5% before induction of general anesthesia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The pericapsular nerve group

patients received Ultrasound guided pericapsular nerve group block using 20 ml of bupivacaine 0.5%

Intervention Type PROCEDURE

Interscalene brachial plexus block

patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5% before induction of general anesthesia

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body mass index \< 40 kg/m2
* American Society of Anesthesiologists (ASA) physical status I-II
* posted for elective shoulder arthroscopy

Exclusion Criteria

* Known allergy to local anesthetics
* allergy to all opioid medications
* diagnostic shoulder arthroscopic procedures
* patients with chronic opioids use and coagulopathy
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kafrelsheikh University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohamed Fouad Algyar

Lecturer of Anaesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Kafrelsheikh University

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mohammed F Algyar, MD

Role: PRINCIPAL_INVESTIGATOR

Lecturer of Anaesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Kafrelsheikh University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mohammed Fouad Mohamed Algyar

Kafr ash Shaykh, Kafrelsheikh, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mohammed F Algyar, MD

Role: CONTACT

00201111645345 ext. 047

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mohammed F Algyar, MD

Role: primary

00201111645345 ext. 047

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MKSU 50-12-7

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.